Featured Story BioCentury & Getty ImagesDebating the fate of innovation

No one believes that H.R. 3, the Democratic House leadership’s drug pricing bill, will be enacted into law , but that hasn’t stopped it from precipitating frenzied debates. The bill has become a ...

Featured Story BioCentury & Getty ImagesSanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron. ...

Featured Story BioCentury & Getty ImagesNew reimbursement models are coming to cancer diagnostics

A newly proposed payment model aims to increase reimbursement for cancer diagnostics by incentivizing companies to produce more clinical utility data. However, to drive widespread adoption, companies ...

Emerging Company Profile BioCentury & Getty ImagesMorphiex’s antisense take on CD47 aims for more than eating

Morphiex is breaking from the CD47 pack by undercutting the target’s expression on both tumor and immune cells instead of just blocking tumors’ “don’t eat me” signals via SIRPA. The company believes ...

Finance DigiTx focuses on data in evolving landscape of digital health investing

As one of the few digital therapeutics-focused investors, DigiTx is parsing opportunities in the rapidly expanding field by homing in on companies that use or generate patient data in innovative ways. ...

Finance BioCentury & Getty ImagesHow Quan intends to build cross-border start-ups with second fund

With a second fund two thirds larger than its first, Quan Capital’s veteran team hopes to take larger stakes in start-ups as it seeks to build cross-border companies in China, the U.S. and Europe. ...

Finance BioCentury & Getty ImagesSyncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 ...

Finance BioCentury & Getty ImagesWith Foresite backing $90M round, GenapSys rolls out a smaller, cheaper sequencer

GenapSys has netted a $90 million series C led by Foresite Capital to introduce a genetic sequencer that is designed to deliver high-accuracy results at low cost without the need for a central ...

BioCentury ISSN 1097-7201